Kam L
University of Southern California School of Medicine, Los Angeles 90033, USA.
Postgrad Med. 1998 Jan;103(1):45-9, 53-6, 59. doi: 10.3810/pgm.1998.01.271.
Ulcerative colitis should be considered in any patient with chronic diarrhea or rectal bleeding. Diagnosis depends on a combination of findings from physical, laboratory, endoscopic, and histopathologic examinations, together with the exclusion of other causes and continued observation over time. The mainstays of treatment are sulfasalazine for mild to moderate disease and corticosteroids for moderate to severe disease. Side effects of sulfasalazine, due to the sulfa moiety of the drug, limit its use in some patients. Newer, sulfa-free 5-ASA agents, although expensive, are appropriate for patients who cannot tolerate sulfasalazine. Refractory ulcerative colitis is best treated surgically. Most patients require maintenance therapy with sulfasalazine or a sulfa-free 5-ASA preparation. Cancer risk is increased in patients with long-standing ulcerative colitis.
任何患有慢性腹泻或直肠出血的患者都应考虑溃疡性结肠炎。诊断取决于体格检查、实验室检查、内镜检查和组织病理学检查结果的综合,同时排除其他病因并长期持续观察。治疗的主要药物是用于轻至中度疾病的柳氮磺胺吡啶和用于中至重度疾病的皮质类固醇。由于药物的磺胺部分,柳氮磺胺吡啶的副作用限制了其在某些患者中的使用。新型无磺胺5-氨基水杨酸制剂虽然昂贵,但适用于不能耐受柳氮磺胺吡啶的患者。难治性溃疡性结肠炎最好通过手术治疗。大多数患者需要用柳氮磺胺吡啶或无磺胺5-氨基水杨酸制剂进行维持治疗。长期溃疡性结肠炎患者的癌症风险会增加。